| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 19 | 2024 | 104 | 5.130 |
Why?
|
| Crohn Disease | 18 | 2026 | 71 | 3.940 |
Why?
|
| Colitis, Ulcerative | 16 | 2026 | 70 | 3.190 |
Why?
|
| Puerto Rico | 46 | 2021 | 1413 | 1.940 |
Why?
|
| Hepatitis C | 9 | 2015 | 139 | 1.450 |
Why?
|
| Liver Transplantation | 6 | 2016 | 37 | 1.410 |
Why?
|
| Cannabis | 2 | 2023 | 90 | 1.300 |
Why?
|
| Tissue and Organ Procurement | 3 | 2014 | 54 | 1.070 |
Why?
|
| Students, Medical | 4 | 2021 | 158 | 1.020 |
Why?
|
| Hepatitis C, Chronic | 6 | 2014 | 44 | 1.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2021 | 989 | 0.980 |
Why?
|
| Cardiovascular Diseases | 3 | 2024 | 749 | 0.970 |
Why?
|
| Adult | 58 | 2026 | 13872 | 0.950 |
Why?
|
| Liver Neoplasms | 5 | 2014 | 224 | 0.950 |
Why?
|
| Middle Aged | 55 | 2026 | 12222 | 0.930 |
Why?
|
| Male | 66 | 2026 | 23409 | 0.920 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2014 | 163 | 0.910 |
Why?
|
| Female | 65 | 2026 | 24698 | 0.890 |
Why?
|
| Humans | 90 | 2026 | 43102 | 0.870 |
Why?
|
| Ostomy | 1 | 2023 | 2 | 0.800 |
Why?
|
| Quality of Life | 5 | 2023 | 616 | 0.800 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2021 | 14 | 0.790 |
Why?
|
| Ribavirin | 5 | 2014 | 21 | 0.770 |
Why?
|
| Prevalence | 16 | 2024 | 1612 | 0.770 |
Why?
|
| Hallucinogens | 1 | 2023 | 29 | 0.760 |
Why?
|
| Young Adult | 22 | 2026 | 5080 | 0.700 |
Why?
|
| Insurance Claim Review | 1 | 2021 | 37 | 0.700 |
Why?
|
| Antiviral Agents | 6 | 2014 | 195 | 0.690 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2020 | 16 | 0.660 |
Why?
|
| Interferon-alpha | 4 | 2011 | 43 | 0.640 |
Why?
|
| Aged | 27 | 2024 | 8214 | 0.640 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2019 | 4 | 0.630 |
Why?
|
| Blood Component Removal | 1 | 2019 | 5 | 0.630 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 73 | 0.610 |
Why?
|
| Antibodies, Monoclonal | 2 | 2019 | 306 | 0.590 |
Why?
|
| Risk Factors | 12 | 2026 | 3994 | 0.530 |
Why?
|
| Hypertension | 1 | 2024 | 835 | 0.510 |
Why?
|
| Tissue Donors | 3 | 2014 | 53 | 0.490 |
Why?
|
| Registries | 4 | 2014 | 437 | 0.490 |
Why?
|
| Polyethylene Glycols | 3 | 2014 | 108 | 0.480 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 760 | 0.470 |
Why?
|
| Papillomavirus Infections | 2 | 2023 | 376 | 0.470 |
Why?
|
| Liver Cirrhosis | 4 | 2014 | 67 | 0.460 |
Why?
|
| Immunoglobulin G | 2 | 2024 | 259 | 0.450 |
Why?
|
| Interleukins | 1 | 2014 | 40 | 0.440 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2026 | 863 | 0.430 |
Why?
|
| Managed Care Programs | 1 | 2013 | 40 | 0.380 |
Why?
|
| Attitude to Health | 2 | 2014 | 338 | 0.380 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2011 | 8 | 0.370 |
Why?
|
| Papillomavirus Vaccines | 1 | 2015 | 174 | 0.370 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2011 | 31 | 0.370 |
Why?
|
| Liver Failure | 2 | 2004 | 6 | 0.370 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 231 | 0.350 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2026 | 734 | 0.340 |
Why?
|
| Retrospective Studies | 10 | 2024 | 2544 | 0.330 |
Why?
|
| Colonic Pouches | 2 | 2009 | 10 | 0.330 |
Why?
|
| Intestinal Fistula | 1 | 2010 | 4 | 0.320 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 14 | 0.320 |
Why?
|
| Recombinant Proteins | 6 | 2014 | 518 | 0.310 |
Why?
|
| Immunologic Factors | 1 | 2010 | 51 | 0.310 |
Why?
|
| Anastomosis, Surgical | 1 | 2009 | 27 | 0.310 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 37 | 0.290 |
Why?
|
| Psoriasis | 1 | 2008 | 19 | 0.290 |
Why?
|
| Immunosuppressive Agents | 2 | 2008 | 94 | 0.290 |
Why?
|
| Public Health | 3 | 2015 | 424 | 0.290 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 165 | 0.290 |
Why?
|
| Organ Transplantation | 1 | 2008 | 24 | 0.280 |
Why?
|
| Abdominal Pain | 1 | 2008 | 24 | 0.270 |
Why?
|
| Child | 8 | 2021 | 3443 | 0.270 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 3156 | 0.270 |
Why?
|
| Adolescent | 14 | 2022 | 6081 | 0.260 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 223 | 0.260 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 590 | 0.260 |
Why?
|
| Weight Loss | 1 | 2008 | 137 | 0.260 |
Why?
|
| Smoking | 1 | 2012 | 1024 | 0.230 |
Why?
|
| Liver Diseases | 3 | 2016 | 34 | 0.220 |
Why?
|
| Health Facilities | 3 | 2011 | 32 | 0.220 |
Why?
|
| Receptors, Calcitriol | 2 | 2016 | 69 | 0.220 |
Why?
|
| Proctocolectomy, Restorative | 2 | 2001 | 21 | 0.220 |
Why?
|
| Pyrophosphatases | 1 | 2024 | 8 | 0.220 |
Why?
|
| Leukopenia | 1 | 2024 | 10 | 0.220 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2004 | 3 | 0.220 |
Why?
|
| HLA Antigens | 3 | 2021 | 27 | 0.220 |
Why?
|
| Health Surveys | 2 | 2020 | 405 | 0.210 |
Why?
|
| Public Assistance | 1 | 2004 | 26 | 0.210 |
Why?
|
| Medically Uninsured | 1 | 2004 | 65 | 0.210 |
Why?
|
| Genital Diseases, Female | 1 | 2023 | 38 | 0.200 |
Why?
|
| Infertility | 1 | 2023 | 21 | 0.200 |
Why?
|
| Ileostomy | 1 | 2023 | 7 | 0.200 |
Why?
|
| Combined Modality Therapy | 3 | 2014 | 173 | 0.200 |
Why?
|
| Age Factors | 3 | 2020 | 1154 | 0.200 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 2853 | 0.200 |
Why?
|
| Cohort Studies | 3 | 2024 | 1759 | 0.190 |
Why?
|
| Hemochromatosis | 2 | 1993 | 3 | 0.190 |
Why?
|
| Hermanski-Pudlak Syndrome | 1 | 2022 | 16 | 0.190 |
Why?
|
| Intestinal Mucosa | 2 | 2016 | 134 | 0.180 |
Why?
|
| Lipids | 2 | 2022 | 256 | 0.180 |
Why?
|
| Schistosomiasis mansoni | 1 | 2001 | 10 | 0.180 |
Why?
|
| Schistosoma mansoni | 1 | 2001 | 21 | 0.180 |
Why?
|
| HLA-DQ Antigens | 1 | 2021 | 6 | 0.170 |
Why?
|
| Age Distribution | 2 | 2020 | 249 | 0.170 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2000 | 14 | 0.170 |
Why?
|
| Prospective Studies | 2 | 2023 | 1600 | 0.170 |
Why?
|
| Libido | 1 | 2020 | 4 | 0.170 |
Why?
|
| Osteotomy | 1 | 2020 | 4 | 0.170 |
Why?
|
| Gene Frequency | 3 | 2021 | 206 | 0.170 |
Why?
|
| Genotype | 4 | 2021 | 800 | 0.160 |
Why?
|
| Perception | 1 | 2021 | 215 | 0.160 |
Why?
|
| Alleles | 3 | 2021 | 352 | 0.160 |
Why?
|
| Anticholesteremic Agents | 1 | 2019 | 25 | 0.150 |
Why?
|
| Health Care Reform | 1 | 1999 | 36 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2001 | 64 | 0.150 |
Why?
|
| Education, Medical, Graduate | 1 | 1999 | 61 | 0.150 |
Why?
|
| Regression Analysis | 1 | 2020 | 490 | 0.150 |
Why?
|
| Analysis of Variance | 1 | 2020 | 575 | 0.150 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1998 | 1 | 0.150 |
Why?
|
| Budd-Chiari Syndrome | 1 | 1998 | 1 | 0.150 |
Why?
|
| Hepatitis, Autoimmune | 1 | 1998 | 2 | 0.150 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1998 | 12 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 310 | 0.140 |
Why?
|
| HIV Infections | 4 | 2010 | 2586 | 0.140 |
Why?
|
| Hospitals, University | 4 | 2007 | 39 | 0.140 |
Why?
|
| Hospitalization | 1 | 2022 | 485 | 0.140 |
Why?
|
| Inflammation | 2 | 2022 | 758 | 0.140 |
Why?
|
| Peptides | 1 | 2021 | 372 | 0.130 |
Why?
|
| Colon | 2 | 2016 | 120 | 0.130 |
Why?
|
| Probability | 2 | 2014 | 82 | 0.120 |
Why?
|
| Sexual Behavior | 2 | 2020 | 638 | 0.120 |
Why?
|
| Interferons | 2 | 2014 | 40 | 0.120 |
Why?
|
| Nocardia | 1 | 2016 | 1 | 0.120 |
Why?
|
| Nocardia Infections | 1 | 2016 | 1 | 0.120 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 1234 | 0.120 |
Why?
|
| Cholestasis | 1 | 2016 | 12 | 0.120 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 934 | 0.120 |
Why?
|
| Time Factors | 4 | 2009 | 1857 | 0.120 |
Why?
|
| Phenotype | 3 | 2026 | 780 | 0.120 |
Why?
|
| Academic Medical Centers | 3 | 2006 | 76 | 0.120 |
Why?
|
| Celiac Disease | 1 | 2015 | 4 | 0.110 |
Why?
|
| Linkage Disequilibrium | 2 | 2021 | 86 | 0.110 |
Why?
|
| Transglutaminases | 1 | 2015 | 7 | 0.110 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2014 | 6 | 0.110 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2015 | 25 | 0.110 |
Why?
|
| Immunoglobulin A | 1 | 2015 | 65 | 0.110 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2014 | 9 | 0.110 |
Why?
|
| Receptors, Interleukin | 1 | 2014 | 11 | 0.110 |
Why?
|
| GTP-Binding Proteins | 1 | 2015 | 59 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2016 | 107 | 0.110 |
Why?
|
| Pouchitis | 2 | 2007 | 4 | 0.110 |
Why?
|
| Waiting Lists | 1 | 2014 | 38 | 0.110 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 116 | 0.110 |
Why?
|
| Prednisone | 2 | 1998 | 31 | 0.110 |
Why?
|
| Spondylitis, Ankylosing | 1 | 1994 | 3 | 0.110 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 1994 | 4 | 0.110 |
Why?
|
| Esophageal Motility Disorders | 1 | 1994 | 1 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2026 | 1285 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2017 | 193 | 0.110 |
Why?
|
| Vitamin D | 1 | 2016 | 196 | 0.100 |
Why?
|
| Forecasting | 1 | 2014 | 136 | 0.100 |
Why?
|
| Esophagus | 1 | 1994 | 42 | 0.100 |
Why?
|
| Survival Rate | 1 | 2014 | 355 | 0.100 |
Why?
|
| Hepatitis B | 2 | 2011 | 41 | 0.100 |
Why?
|
| Vaginal Smears | 1 | 2014 | 63 | 0.100 |
Why?
|
| United States | 7 | 2026 | 5205 | 0.100 |
Why?
|
| Government | 1 | 2013 | 8 | 0.100 |
Why?
|
| Infant | 2 | 2014 | 1175 | 0.100 |
Why?
|
| Data Collection | 1 | 2013 | 210 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2011 | 1604 | 0.100 |
Why?
|
| Chronic Disease | 3 | 2022 | 549 | 0.100 |
Why?
|
| Surgical Procedures, Operative | 1 | 2012 | 33 | 0.090 |
Why?
|
| Hepatitis C Antibodies | 2 | 2009 | 10 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2014 | 1546 | 0.090 |
Why?
|
| Commerce | 1 | 2013 | 95 | 0.090 |
Why?
|
| Hepatitis B Vaccines | 1 | 2011 | 12 | 0.090 |
Why?
|
| Minority Groups | 3 | 2006 | 690 | 0.090 |
Why?
|
| Government Programs | 1 | 2011 | 29 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2011 | 102 | 0.080 |
Why?
|
| Hepatolenticular Degeneration | 1 | 1990 | 2 | 0.080 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1991 | 42 | 0.080 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2010 | 12 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2015 | 367 | 0.080 |
Why?
|
| Herpes Simplex | 1 | 2010 | 19 | 0.080 |
Why?
|
| Biopsy, Needle | 3 | 1999 | 59 | 0.080 |
Why?
|
| Medically Underserved Area | 1 | 2011 | 120 | 0.080 |
Why?
|
| Colonoscopy | 2 | 2008 | 122 | 0.080 |
Why?
|
| Phenytoin | 1 | 1989 | 2 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2007 | 1067 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2009 | 368 | 0.080 |
Why?
|
| Hepatectomy | 1 | 2009 | 8 | 0.080 |
Why?
|
| Specimen Handling | 1 | 2010 | 63 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 113 | 0.070 |
Why?
|
| Genome-Wide Association Study | 2 | 2026 | 423 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 512 | 0.070 |
Why?
|
| Duodenitis | 1 | 1988 | 2 | 0.070 |
Why?
|
| Risk | 1 | 2009 | 287 | 0.070 |
Why?
|
| Peptic Ulcer | 1 | 1988 | 15 | 0.070 |
Why?
|
| Gastritis | 1 | 1988 | 13 | 0.070 |
Why?
|
| Osteoarthritis | 1 | 1988 | 25 | 0.070 |
Why?
|
| Gastric Mucosa | 1 | 1988 | 65 | 0.070 |
Why?
|
| Physician's Role | 1 | 2008 | 40 | 0.070 |
Why?
|
| Seroepidemiologic Studies | 4 | 2010 | 74 | 0.070 |
Why?
|
| Health Education | 1 | 2011 | 363 | 0.070 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 118 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1988 | 58 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2009 | 131 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 518 | 0.070 |
Why?
|
| Haplotypes | 2 | 2021 | 197 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1988 | 146 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2010 | 760 | 0.060 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2007 | 20 | 0.060 |
Why?
|
| Liver | 4 | 2016 | 511 | 0.060 |
Why?
|
| Malignant Carcinoid Syndrome | 1 | 1986 | 1 | 0.060 |
Why?
|
| Biopsy | 3 | 2016 | 177 | 0.060 |
Why?
|
| Internal Medicine | 1 | 2006 | 32 | 0.060 |
Why?
|
| Faculty, Medical | 1 | 2006 | 74 | 0.060 |
Why?
|
| Health Promotion | 1 | 2011 | 704 | 0.060 |
Why?
|
| Chordoma | 1 | 2004 | 1 | 0.060 |
Why?
|
| Skull Base Neoplasms | 1 | 2004 | 1 | 0.060 |
Why?
|
| Antirheumatic Agents | 1 | 2005 | 37 | 0.060 |
Why?
|
| Indians, South American | 1 | 2024 | 9 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2001 | 263 | 0.050 |
Why?
|
| Postoperative Care | 1 | 2004 | 20 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2004 | 32 | 0.050 |
Why?
|
| Iron | 3 | 2007 | 251 | 0.050 |
Why?
|
| Jejunal Neoplasms | 1 | 1984 | 1 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2004 | 245 | 0.050 |
Why?
|
| Cultural Diversity | 1 | 2006 | 193 | 0.050 |
Why?
|
| Mesenteric Arteries | 1 | 1984 | 20 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 67 | 0.050 |
Why?
|
| Anemia, Hemolytic | 1 | 2003 | 8 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2024 | 68 | 0.050 |
Why?
|
| Insurance Carriers | 1 | 2003 | 2 | 0.050 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2003 | 19 | 0.050 |
Why?
|
| Folic Acid | 1 | 2003 | 49 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 127 | 0.050 |
Why?
|
| Hemorrhagic Disorders | 1 | 2022 | 1 | 0.050 |
Why?
|
| Albinism | 1 | 2022 | 2 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2003 | 110 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 1999 | 238 | 0.050 |
Why?
|
| Latin America | 1 | 2022 | 55 | 0.050 |
Why?
|
| HIV-1 | 1 | 2008 | 755 | 0.050 |
Why?
|
| Caribbean Region | 1 | 2022 | 79 | 0.040 |
Why?
|
| Risk-Taking | 1 | 2005 | 457 | 0.040 |
Why?
|
| Antibodies, Helminth | 1 | 2001 | 24 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 306 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 1984 | 291 | 0.040 |
Why?
|
| Vaccination | 1 | 2024 | 355 | 0.040 |
Why?
|
| Algorithms | 1 | 2004 | 509 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 1019 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2001 | 165 | 0.040 |
Why?
|
| Bone Density | 1 | 2000 | 103 | 0.040 |
Why?
|
| Proteomics | 1 | 2022 | 378 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 458 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2001 | 187 | 0.040 |
Why?
|
| Echinococcosis, Hepatic | 1 | 1999 | 1 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2004 | 587 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2024 | 1271 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2004 | 706 | 0.040 |
Why?
|
| Ileitis | 1 | 1998 | 2 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 1998 | 7 | 0.040 |
Why?
|
| Cerebral Infarction | 1 | 1998 | 19 | 0.040 |
Why?
|
| Recurrence | 2 | 2016 | 152 | 0.040 |
Why?
|
| Angiography, Digital Subtraction | 1 | 1998 | 9 | 0.040 |
Why?
|
| Incidence | 1 | 2022 | 1078 | 0.040 |
Why?
|
| Ultrasonography | 1 | 1998 | 135 | 0.030 |
Why?
|
| Prognosis | 2 | 2017 | 861 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 1998 | 93 | 0.030 |
Why?
|
| Ferritins | 2 | 1998 | 63 | 0.030 |
Why?
|
| Protein Binding | 1 | 2021 | 1082 | 0.030 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 1996 | 1 | 0.030 |
Why?
|
| Splenorenal Shunt, Surgical | 1 | 1996 | 1 | 0.030 |
Why?
|
| Sclerotherapy | 1 | 1996 | 3 | 0.030 |
Why?
|
| Propranolol | 1 | 1996 | 18 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1998 | 187 | 0.030 |
Why?
|
| Colonic Diseases | 2 | 2006 | 11 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2004 | 234 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2016 | 43 | 0.030 |
Why?
|
| Hemoglobins | 2 | 2007 | 113 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2016 | 182 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 280 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2015 | 107 | 0.030 |
Why?
|
| Peristalsis | 1 | 1994 | 1 | 0.030 |
Why?
|
| Heartburn | 1 | 1994 | 2 | 0.030 |
Why?
|
| Esophageal Achalasia | 1 | 1994 | 3 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 88 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 863 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 1996 | 287 | 0.030 |
Why?
|
| Chest Pain | 1 | 1994 | 49 | 0.030 |
Why?
|
| Deglutition Disorders | 1 | 1994 | 25 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2012 | 10 | 0.020 |
Why?
|
| Pregnancy | 1 | 1998 | 1772 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2015 | 986 | 0.020 |
Why?
|
| Bloodletting | 1 | 1991 | 1 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1990 | 35 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 138 | 0.020 |
Why?
|
| Hemolysis | 1 | 1990 | 60 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 154 | 0.020 |
Why?
|
| Meningioma | 1 | 1989 | 7 | 0.020 |
Why?
|
| France | 1 | 2009 | 23 | 0.020 |
Why?
|
| Founder Effect | 1 | 2009 | 10 | 0.020 |
Why?
|
| North America | 1 | 2009 | 85 | 0.020 |
Why?
|
| Seizures | 1 | 1989 | 79 | 0.020 |
Why?
|
| Canada | 1 | 2009 | 163 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 259 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2009 | 68 | 0.020 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 1988 | 3 | 0.020 |
Why?
|
| Gastroscopy | 1 | 1988 | 9 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2008 | 28 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2008 | 20 | 0.020 |
Why?
|
| Markov Chains | 1 | 2008 | 43 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2001 | 638 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2008 | 87 | 0.020 |
Why?
|
| Selection, Genetic | 1 | 2008 | 75 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2008 | 150 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2008 | 121 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 1989 | 140 | 0.020 |
Why?
|
| Genome, Human | 1 | 2008 | 144 | 0.020 |
Why?
|
| Observer Variation | 1 | 2007 | 59 | 0.020 |
Why?
|
| ROC Curve | 1 | 2007 | 159 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2007 | 23 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1009 | 0.020 |
Why?
|
| Animals | 2 | 2001 | 16992 | 0.020 |
Why?
|
| Erythema Nodosum | 1 | 2006 | 2 | 0.020 |
Why?
|
| Stomach Diseases | 1 | 2006 | 5 | 0.020 |
Why?
|
| Esophageal Diseases | 1 | 2006 | 4 | 0.020 |
Why?
|
| Duodenal Diseases | 1 | 2006 | 3 | 0.020 |
Why?
|
| Uveitis | 1 | 2006 | 5 | 0.020 |
Why?
|
| Sacroiliac Joint | 1 | 2006 | 3 | 0.020 |
Why?
|
| Software | 1 | 2008 | 236 | 0.020 |
Why?
|
| Rectal Diseases | 1 | 2006 | 4 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1988 | 226 | 0.020 |
Why?
|
| School Admission Criteria | 1 | 2006 | 10 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 611 | 0.010 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 1985 | 1 | 0.010 |
Why?
|
| Intestinal Obstruction | 1 | 1985 | 4 | 0.010 |
Why?
|
| Body Piercing | 1 | 2005 | 2 | 0.010 |
Why?
|
| Tattooing | 1 | 2005 | 7 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2005 | 31 | 0.010 |
Why?
|
| Heroin Dependence | 1 | 2005 | 23 | 0.010 |
Why?
|
| Health Occupations | 1 | 2005 | 19 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2005 | 91 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 224 | 0.010 |
Why?
|
| Neurosurgical Procedures | 1 | 2004 | 26 | 0.010 |
Why?
|
| Cocaine-Related Disorders | 1 | 2005 | 102 | 0.010 |
Why?
|
| Radiography | 1 | 1984 | 71 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 719 | 0.010 |
Why?
|
| Haptoglobins | 1 | 2003 | 10 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 1081 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2001 | 236 | 0.010 |
Why?
|
| Mebendazole | 1 | 1999 | 4 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 1999 | 10 | 0.010 |
Why?
|
| Anthelmintics | 1 | 1999 | 23 | 0.010 |
Why?
|
| Clinical Enzyme Tests | 1 | 1998 | 7 | 0.010 |
Why?
|
| gamma-Glutamyltransferase | 1 | 1998 | 9 | 0.010 |
Why?
|
| Transaminases | 1 | 1998 | 8 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1998 | 54 | 0.010 |
Why?
|
| Sex Factors | 1 | 2001 | 1028 | 0.010 |
Why?
|
| Cecal Diseases | 1 | 1985 | 2 | 0.000 |
Why?
|
| Cerebral Hemorrhage | 1 | 1985 | 104 | 0.000 |
Why?
|